502. Leung A. M., Hari D. M., Morton D. L. Surgery for distant melanoma metastasis // Cancer J. ‒ 2012. ‒ T. 18, № 2. ‒ C. 176-84.
503. Creech O., Jr., Ryan R. F., Krementz E. T. Treatment of melanoma by isolation-perfusion technique // J Am Med Assoc. ‒ 1959. ‒ T. 169, № 4. ‒ C. 339-43.
504. Thompson J. F., Lai D. T., Ingvar C., Kam P. C. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma // Melanoma Res. ‒ 1994. ‒ T. 4 Suppl 1. ‒ C. 45-50.
505. Moreno-Ramirez D., de la Cruz-Merino L., Ferrandiz L., Villegas-Portero R., Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety // Oncologist. ‒ 2010. ‒ T. 15, № 4. ‒ C. 416-27.
506. Cornett W. R., McCall L. M., Petersen R. P., Ross M. I., Briele H. A., Noyes R. D., Sussman J. J., Kraybill W. G., Kane J. M., 3rd, Alexander H. R., Lee J. E., Mansfield P. F., Pingpank J. F., Winchester D. J., White R. L., Jr., Chadaram V., Herndon J. E., 2nd, Fraker D. L., Tyler D. S., American College of Surgeons Oncology Group Trial Z. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 // J Clin Oncol. ‒ 2006. ‒ T. 24, № 25. ‒ C. 4196-201.
507. Hyde M. A., Hadley M. L., Tristani-Firouzi P., Goldgar D., Bowen G. M. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions // Arch Dermatol. ‒ 2012. ‒ T. 148, № 5. ‒ C. 592-6.
508. Cotter M. A., McKenna J. K., Bowen G. M. Treatment of lentigo maligna with imiquimod before staged excision // Dermatol Surg. ‒ 2008. ‒ T. 34, № 2. ‒ C. 147-51.
509. Naylor M. F., Crowson N., Kuwahara R., Teague K., Garcia C., Mackinnis C., Haque R., Odom C., Jankey C., Cornelison R. L. Treatment of lentigo maligna with topical imiquimod // Br J Dermatol. ‒ 2003. ‒ T. 149 Suppl 66. ‒ C. 66-70.
510. Youland R. S., Blanchard M. L., Dronca R., Kottschade L., Markovic S. N., Olivier K. R., Park S. S. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era // Clin Transl Radiat Oncol. ‒ 2017. ‒ T. 6. ‒ C. 25-30.
511. Seegenschmiedt M. H., Keilholz L., Altendorf-Hofmann A., Urban A., Schell H., Hohenberger W., Sauer R. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience // Int J Radiat Oncol Biol Phys. ‒ 1999. ‒ T. 44, № 3. ‒ C. 607-18.
512. McQuay H. J., Collins S. L., Carroll D., Moore R. A. Radiotherapy for the palliation of painful bone metastases // Cochrane Database Syst Rev. ‒ 2000.10.1002/14651858.CD001793 № 2. ‒ C. CD001793.
513. Liew D. N., Kano H., Kondziolka D., Mathieu D., Niranjan A., Flickinger J. C., Kirkwood J. M., Tarhini A., Moschos S., Lunsford L. D. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article // J Neurosurg. ‒ 2011. ‒ T. 114, № 3. ‒ C. 769-79.
514. Atkins M. B., Sosman J. A., Agarwala S., Logan T., Clark J. I., Ernstoff M. S., Lawson D., Dutcher J. P., Weiss G., Curti B., Margolin K. A. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study // Cancer. ‒ 2008. ‒ T. 113, № 8. ‒ C. 2139-45.
515. Sperduto P. W., Mesko S., Li J., Cagney D., Aizer A., Lin N. U., Nesbit E., Kruser T. J., Chan J., Braunstein S., Lee J., Kirkpatrick J. P., Breen W., Brown P. D., Shi D., Shih H. A., Soliman H., Sahgal A., Shanley R., Sperduto W. A., Lou E., Everett A., Boggs D. H., Masucci L., Roberge D., Remick J., Plichta K., Buatti J. M., Jain S., Gaspar L. E., Wu C.-C., Wang T. J. C., Bryant J., Chuong M., An Y., Chiang V., Nakano T., Aoyama H., Mehta M. P. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient // Journal of Clinical Oncology. ‒ 2020. ‒ T. 38, № 32. ‒ C. 3773-3784.
516. Komori T., Otsuka A., Kusuba N., Taniguchi K., Endo Y., Honda T., Kabashima K. Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy // Eur J Dermatol. ‒ 2017. ‒ T. 27, № 5. ‒ C. 548-549.
517. Samoylenko I. V., Kolontareva Y. M., Kogay E. V., Zhukova N. V., Utyashev I. A., Ivannikov M. E., Menshikov K. V., Zinkevich M. V., Orlova K. V., Vakhabova Y. V., Volkonsky M. V., Beliaeva N. A., Butkov, II, Karabina E. V., Moskovkina T. L., Moshkova K. A., Plishkina O. V., Sychev V. D., Cheplukhova O. S., Chernova V. V., Yurchenkov A. N., Babina K. G., Savelov N. A., Demidov L. V. Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study // Front Oncol. ‒ 2024. ‒ T. 14. ‒ C. 1395378.
518. Dummer R., Queirolo P., Gerard Duhard P., Hu Y., Wang D., de Azevedo S. J., Robert C., Ascierto P. A., Chiarion-Sileni V., Pronzato P., Spagnolo F., Mujika Eizmendi K., Liszkay G., de la Cruz Merino L., Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study // Lancet Oncol. ‒ 2023. ‒ T. 24, № 12. ‒ C. e461-e471.
519. Zhuang H., Shi S., Yuan Z., Chang J. Y. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues // Mol Cancer. ‒ 2019. ‒ T. 18, № 1. ‒ C. 21.